Search Patents
  • SIALIC ACID COMPOSITIONS FOR THE USE OF INHIBITING AND TREATING CORONAVIRUS INFECTION
    Publication number: 20230128687
    Abstract: The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).
    Type: Application
    Filed: March 31, 2021
    Publication date: April 27, 2023
    Inventor: Jan Remmereit
  • SIALIC ACID COMPOSITIONS FOR THE USE OF INHIBITING AND TREATING CORONAVIRUS INFECTION
    Publication number: 20240148763
    Abstract: The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).
    Type: Application
    Filed: November 13, 2023
    Publication date: May 9, 2024
    Inventor: Jan Remmereit
  • Sialic acid compositions for the use of inhibiting and treating coronavirus infection
    Patent number: 11813271
    Abstract: The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: November 14, 2023
    Assignee: LifeScience AS
    Inventor: Jan Remmereit
  • METHODS AND COMPOSITIONS FOR TREATING SUBJECTS WITH METABOLIC DISORDERS AND CORONAVIRUS INFECTIONS
    Publication number: 20230210825
    Abstract: Provided herein are thiazolidinedione analogues that are useful for treating metabolic disorders and/or coronavirus infections. In some embodiments, the metabolic disorder includes insulin resistance, diabetes, or prediabetes. In some embodiments, the coronavirus is COVID-19.
    Type: Application
    Filed: October 14, 2022
    Publication date: July 6, 2023
    Inventor: Gerard R. COLCA
  • MONOCLONAL ANTIBODY AGAINST NOVEL CORONAVIRUS AND APPLICATION THEREOF
    Publication number: 20230116587
    Abstract: Provided are a monoclonal antibody against a novel coronavirus and a composition that comprises said antibody. The antibody can be used to diagnose, prevent and/or treat novel coronavirus infections and/or diseases caused by an infection.
    Type: Application
    Filed: March 12, 2021
    Publication date: April 13, 2023
    Inventors: Xiaoliang Sunney XIE, Yunlong CAO, Wenjie SUN
  • Compositions and methods for coronavirus inhibition
    Patent number: 9056900
    Abstract: The present invention provides compositions and methods for treating a coronavirus infection. A method embodiment comprises administering a polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a coronavirus infection. The polypeptide comprises or consists of at least a portion of the fusion initiation region (FIR) of a coronavirus fusion protein. In some embodiments, the polypeptide comprises or consists of a sequence selected from SEQ ID NO: 2, 22, 23, 24, and 25 or an 8 to 40 contiguous amino acid residue portion thereof.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: June 16, 2015
    Assignees: The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLC.
    Inventors: Robert F. Garry, Russell B. Wilson
  • METHODS FOR TREATING CORONAVIRUS INFECTION
    Publication number: 20220233468
    Abstract: The present invention provides methods for treating or preventing coronavirus infection, or a coronavirus-associated disease, condition, or symptom in a subject. In particular, the methods comprise administering a transmembrane protease serine 2 (TMPRSS2) inhibitor, or a pharmaceutically acceptable salt or tautomer thereof.
    Type: Application
    Filed: January 27, 2022
    Publication date: July 28, 2022
    Inventor: Shauh-Der YEH
  • Anti-coronavirus drug
    Publication number: 20060223847
    Abstract: The present invention provides an anti-coronavirus agent including as an active ingredient as exemplified by nelfinavir and salts thereof, an anti-SARS agent including the anti-coronavirus agent, and a method of treating SARS using the anti-SARS agent.
    Type: Application
    Filed: July 14, 2004
    Publication date: October 5, 2006
    Applicant: Arigen, Inc.
    Inventors: Nobutaka Fujii, Naoki Yamamoto
  • Method of manufacturing coronavirus diagnostic kit, virus diagnostic kit manufactured thereby and method of diagnosing coronavirus using the same
    Patent number: 11976338
    Abstract: Provided are a method of manufacturing a coronavirus diagnostic kit, which includes preparing a one-component primer/probe mixture by mixing a primer set including a primer pair consisting of base sequences of SEQ ID NOs: 1 and 2, a primer pair consisting of base sequences of SEQ ID NOs: 3 and 4, a primer pair consisting of base sequences of SEQ ID NOs: 5 and 6, and a primer pair consisting of base sequences of SEQ ID NOs: 7 and 8; and a probe consisting of a base sequence of SEQ ID NO: 9, a probe consisting of a base sequence of SEQ ID NO: 10, a probe consisting of a base sequence of SEQ ID NO: 11, and a probe consisting of a base sequence of SEQ ID NO: 12, a coronavirus diagnostic kit manufactured using the same, and a method of diagnosing coronavirus using the same.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: May 7, 2024
    Assignee: OSANG HEALTHCARE CO., LTD.
    Inventors: Joo Hyung Kim, Go Woon Cha
  • COBICISTAT FOR PREVENTION AND/OR TREATMENT OF CORONAVIRUS INFECTIONS
    Publication number: 20230107186
    Abstract: The present invention relates to cobicistat and its derivatives or prodrugs for use in the prophylaxis and/or treatment of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, severe acute respiratory syndrome coronavirus (SARS-CoV) infection and/or Middle East respiratory syndrome coronavirus (MERS-CoV) infection. The present invention further relates to methods of prevention and/or treatment of SARS-CoV-2 infection.
    Type: Application
    Filed: March 5, 2021
    Publication date: April 6, 2023
    Inventors: MOHAMED OMAR FARES, MAHMOUD MOSTAFA TOLBA, AHMED TAHA AYOUB, MARINA LUSIC, IART LUCA SHYTAJ, ANDREA SAVARINO, RICARDO SOBHIE DIAZ
  • COMPOSITIONS AND METHODS FOR CORONAVIRUS INHIBITION
    Publication number: 20140045743
    Abstract: The present invention provides compositions and methods for treating a coronavirus infection. A method embodiment comprises administering a polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a coronavirus infection. The polypeptide comprises or consists of at least a portion of the fusion initiation region (FIR) of a coronavirus fusion protein. In some embodiments, the polypeptide comprises or consists of a sequence selected from SEQ ID NO: 2, 22, 23, 24, and 25 or an 8 to 40 contiguous amino acid residue portion thereof.
    Type: Application
    Filed: August 8, 2013
    Publication date: February 13, 2014
    Applicants: Autoimmune Technologies, LLC, The Administrators of the Tulane Educational Fund
    Inventors: Robert F. GARRY, Russell B. WILSON, I
  • METHOD OF MANUFACTURING CORONAVIRUS DIAGNOSTIC KIT, VIRUS DIAGNOSTIC KIT MANUFACTURED THEREBY AND METHOD OF DIAGNOSING CORONAVIRUS USING THE SAME
    Publication number: 20230147691
    Abstract: Provided are a method of manufacturing a coronavirus diagnostic kit, which includes preparing a one-component primer/probe mixture by mixing a primer set including a primer pair consisting of base sequences of SEQ ID NOs: 1 and 2, a primer pair consisting of base sequences of SEQ ID NOs: 3 and 4, a primer pair consisting of base sequences of SEQ ID NOs: 5 and 6, and a primer pair consisting of base sequences of SEQ ID NOs: 7 and 8; and a probe consisting of a base sequence of SEQ ID NO: 9, a probe consisting of a base sequence of SEQ ID NO: 10, a probe consisting of a base sequence of SEQ ID NO: 11, and a probe consisting of a base sequence of SEQ ID NO: 12, a coronavirus diagnostic kit manufactured using the same, and a method of diagnosing coronavirus using the same.
    Type: Application
    Filed: April 22, 2020
    Publication date: May 11, 2023
    Inventors: Joo Hyung KIM, Go Woon CHA
  • THERAPEUTIC AGENT FOR CORONAVIRUS INFECTION
    Publication number: 20230127703
    Abstract: Coronavirus infection can be treated by administering a pharmaceutical composition comprising 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof as an active ingredient to coronavirus infection patient with non-serious pneumonia.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 27, 2023
    Applicant: FUJIFILM Toyama Chemical Co., Ltd.
    Inventor: Tsutomu SAKURAI
  • MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES
    Publication number: 20240066114
    Abstract: The present invention is inter alia directed to compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein selected or derived from a Coronavirus membrane protein (M), nucleocapsid protein (N), non-structural protein, and/or accessory protein or an immunogenic fragment or immunogenic variant thereof. The composition may additionally comprise at least one nucleic acid encoding at least one antigenic peptide or protein selected or derived from a Coronavirus spike protein (S). The nucleic acid sequences of the compositions are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The compositions provided herein are for use in treatment or prophylaxis of an infection with at least one Coronavirus, and may therefore be comprised in a vaccine, preferably a multivalent vaccine.
    Type: Application
    Filed: August 30, 2021
    Publication date: February 29, 2024
    Applicant: CureVac SE
    Inventors: Susanne RAUCH, Nicole ROTH, Benjamin PETSCH, Wolfgang GROSSE
  • PARAPOXVIRUS FOR CONDITIONING FOR AND TREATMENT OF CORONAVIRUS INFECTIONS
    Publication number: 20220401553
    Abstract: The present invention relates to the treatment of coronavirus infections and to preparing subjects for such an infection by administering a parapoxvirus. This treatment is to assist the immune system in combatting the virus and to thereby prevent and to ameliorate symptoms of coronavirus disease.
    Type: Application
    Filed: May 10, 2021
    Publication date: December 22, 2022
    Inventors: Daniela Paulsen, Alexander Birkmann, Peter Lischka, Tamara Pfaff, Holger Zimmermann
  • TREATMENT FOR CORONAVIRUS INFECTION AND ASSOCIATED CYTOKINE TOXICITY
    Publication number: 20230201250
    Abstract: The present invention relates to novel methods for treating or preventing coronavirus infection and cytokine-associated toxicity, including cytokine toxicity resulting from aberrant activation of the immune system in coronavirus disease or infection, such as those from SARS-CoV-2.
    Type: Application
    Filed: November 30, 2022
    Publication date: June 29, 2023
    Inventor: Sydney David Cullis-Hill
  • ANTIBODIES TO CORONAVIRUS SPIKE PROTEIN AND METHODS OF USE THEREOF
    Publication number: 20230399384
    Abstract: Provided herein are antibodies binding to Coronavirus S protein and the uses of the antibodies in detecting and treating Coronavirus infection, such as COVID-19.
    Type: Application
    Filed: April 22, 2021
    Publication date: December 14, 2023
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zhiqiang KU, Ningyan ZHANG, Zhiqiang AN, Xuping XIE, Pei-Yong SHI
  • METHOD PREPARING SILVER-NANOCURCUMIN MATERIAL FOR INHIBITING NEW CORONAVIRUS
    Publication number: 20220160673
    Abstract: The present disclosure provides a method preparing Silver-nanocurcumin material for inhibiting new coronavirus. The turmeric powder is heated and stirred and then mixed with silver nitrate solution. After multiple steps of cooling, stirring for reaction and centrifuging and other steps, crude extract of Silver-nanocurcumin is obtained. Then, after further processes such as the multiple washing and centrifuging, a purified composition of Silver-nanocurcumin is obtained. The composition of Silver-nanocurcumin can be used to inhibit the new coronavirus and its similar viruses, and as a source of drugs for the prevention and treatment of diseases derived from the new coronavirus COVID-19 in the future.
    Type: Application
    Filed: November 24, 2020
    Publication date: May 26, 2022
    Inventor: Chih-Chang Lai
  • LARGE SEQUENCE PAN-CORONAVIRUS VACCINE COMPOSITIONS
    Publication number: 20230173060
    Abstract: Pan-coronavirus vaccines for inducing efficient, powerful and long-lasting protection against all Coronaviruses infections and diseases, comprising multiple highly conserved large sequences which may comprise one or more conserved B, CD4 and CD8 T cell epitopes that help provide multiple targets for the body to develop an immune response for preventing a Coronavirus infection and/or disease. In certain embodiments, the large sequences are conserved proteins or large sequences, e.g., sequences that are highly conserved among human coronaviruses and/or animal coronaviruses (e.g., coronaviruses isolated from animals susceptible to coronavirus infections).
    Type: Application
    Filed: October 14, 2022
    Publication date: June 8, 2023
    Inventor: Lbachir BenMohamed
  • MULTIMERIC CORONAVIRUS BINDING MOLECULES AND USES THEREOF
    Publication number: 20220403009
    Abstract: This disclosure provides multimeric binding molecules that bind to a human coronavirus, e.g., MERS-CoV, SARS-CoV or SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing human coronavirus disease, e.g., coronavirus disease 2019 (COVID-19).
    Type: Application
    Filed: July 14, 2022
    Publication date: December 22, 2022
    Inventors: Paul R. Hinton, Bruce Alan Keyt, Dean Ng, Kathy Miller, Deepal Pandya, Stephen F. Carroll
Narrow Results

Filter by US Classification